Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Pentoxifylline-Tocopherol-Clodronate

PreclinicalSmall molecule

UUniversity Hospital, Brest

Pentoxifylline-Tocopherol-Clodronate is one of 2 small molecule programs targeting Osteoradionecrosis. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteoradionecrosisActive, not recruiting

OsteoradionecrosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Osteoradionecrosis

#DrugCompanyPhaseTrials

Hyperbaric Oxygen

IIntermountain Health Care, Inc.

Pentoxifylline-Tocopherol-Clodronate

UUniversity Hospital, Brest

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteoradionecrosis1 trial

Osteoradionecrosis and PENTOCLO Protocol: Retrospective Study

Completed·UUniversity Hospital, Brest··NCT04097847·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pentoxifylline-Tocopherol-Clodronate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pentoxifylline-Tocopherol-Clodronate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pentoxifylline-Tocopherol-Clodronate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Brest company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Brest

Related News